AKT1 and breast cancer: Baicalein (10–15 μM) reduces adhesion, migration, and invasion in MCF-7 and SK-BR-3 BC cells by suppressing ERK1/2 and AKT signaling pathways, which are initiated through E2-induced GPR30-mediated EGFR activation [108, 109].